Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;35(12):e15969.
doi: 10.1111/dth.15969. Epub 2022 Nov 9.

Simvastatin and non-segmental vitiligo: A new potential treatment option?

Engi Seif E Shaker  1 , Sherihan H Allam  2 , Maaly M Mabrouk  3 , Nashwa M Elgharbawy  4 , Shady Fikry Abdel Salaam  1
Affiliations

Simvastatin and non-segmental vitiligo: A new potential treatment option?

Engi Seif E Shaker et al. Dermatol Ther. 2022 Dec.

Abstract

There is a paucity of data about the impact of systemic statins on vitiliginous lesions in non-segmental vitiligo (NSV) patients. To the best of our knowledge, no other studies have considered the correlation between lipid disturbances in vitiligo and vitiligo disease activity (VIDA) score. We sought in this study to evaluate the influence of simvastatin on vitiliginous lesions in NSV patients with dyslipidemia and study the correlation between VIDA score and lipid profile. This clinical trial started with 120 patients with NSV, 79 patients had dyslipidemia and received simvastatin 80 mg daily (till normalization of lipid profile or for 4 months, which came first) and only 63 patients continued till the end of the study. Lipid profile, vitiligo area severity index and VIDA were assessed before and 6 months after the end of simvastatin use. Serum total cholesterol (TC), triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein, and LDL/HDL ratio showed statistically significant increases in the NSV than in the control group (p ˂ 0.001). There was a statistically significant positive correlation between VIDA and serum levels of TC and LDL and with LDL/HDL ratio. Simvastatin significantly improved the lipid profile and significantly decreased VIDA (p < 0.011). Negative moderate correlation was found between the decrease in VIDA and duration of disease (r = -0.562, p < 0.001). Simvastatin 80 mg daily could be a helpful treatment for NSV patients with dyslipidemia, controlling the vitiligo activity and protecting against the hazardous effects of dyslipidemia. Better results can be obtained in patients with short duration of the disease.

Keywords: Dyslipidemia; Non-segmental; Simvastatin; Vitiligo.

PubMed Disclaimer

References

REFERENCES

    1. Passeron T, Ortonne J. Vitiligo and other disorders of hypopigmentation. In: Bolognia J, Schaffer J, Cerroni L, et al., eds. Bolognia Textbook of Dermatology. 4th ed. Elsevier; 2018:1090-1092.
    1. Guerra L, Dellambra E, Brescia S, Raskovic D. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab. 2010;11(5):451-467. doi:10.2174/138920010791526105
    1. Solak B, Dikicier BS, Cosansu NC, et al. Neutrophil to lymphocyte ratio in patients with vitiligo. Postepy Dermatologii i Alergologii. 2017;34(5):468-470. doi:10.5114/ada.2017.71114
    1. Karadag AS, Tutal E, Ertugrul DT. Insulin resistance is increased in patients with vitiligo. Acta Derm Venereol. 2011;91(5):541-544. doi:10.2340/00015555-1141
    1. Pietrzak A, Bartosinska J, Dybiec E, et al. Hepato-splenic and lipid profile abnormalities - do they exist in children affected with vitiligo? Acta Dermatovenerol Croatica. 2014;22(1):19-25.

LinkOut - more resources